> Back to EJC

Recent editions

  • November 2016
    Mike Stratton on how mutational changes in a cancer genome can point to the cause of the cancer.
  • October 2016
    Ruth Muschel on a new target for treatments for colorectal cancer.
  • September 2016
    Freddie Hamdy on the effectiveness of treatments for prostate cancer.
  • August 2016
    Moshe Oren discusses the effects of the microenvironment on cancer cells.
  • July 2016
    Richard Gilbertson on the 'bad luck hypothesis' for the cause of cancer.
  • June 2016
    Key advances in clinical trials.
  • May 2016
    Mark Lemmon on the underlying biochemistry of cancer.
  • April 2016
    Roger Stupp on using alternating electric fields as treatment.
  • March 2016
    Charlotte Vrinten on public perception of deaths from cancer.
  • February 2016
    Guillermo Garcia-Manero on myelodysplastic syndromes (MDS).
  • December 2015/January 2016
    Nazneen Rahman on germline genetic screening in ovarian cancer.

> All 2015 Editions

> All 2014 Editions

> All 2013 Editions

> All 2012 Editions

> All 2011 Editions

EJC News Focus – February 2016

Loading EJC News Focus video

Unravelling the mysteries of MDS

All cancers have some epigenetic component, but myelodysplastic syndromes (MDS) are the only diseases in which hypomethylating agents have had significant clinical activity. Colon cancer, for example has as much methylation as MDS but is resistant to these agents. Why that should be remains a mystery.

At the European Cancer Congress in Vienna (September 2015), Guillermo Garcia-Manero (MD Anderson Cancer Center, Houston, Texas) presented research into this and other difficult questions in MDS. In this EJC News Focus, he tells Helen Saul that the eventual answers could have implications in a wide range of cancers.